350
Participants
Start Date
March 31, 2021
Primary Completion Date
March 2, 2026
Study Completion Date
March 2, 2026
Rate control
Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.
NOT_YET_RECRUITING
Hvidovre University Hospital, Hvidovre
NOT_YET_RECRUITING
Zealand University Hospital - Roskilde, Roskilde
RECRUITING
Holbæk Hospital, Holbæk
NOT_YET_RECRUITING
Odense University Hospital, Odense
Odense University Hospital
OTHER
Hvidovre University Hospital
OTHER
Zealand University Hospital
OTHER
Holbaek Sygehus
OTHER